Replimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REPL

LOS ANGELES--(BUSINESS WIRE)--The DJS Law Group reminds investors of a class action lawsuit against Replimune Group, Inc. (“Replimune” or “the Company”) (NASDAQ: REPL) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.

CLASS PERIOD: October 20, 2025 to April 10, 2026

DEADLINE: October 5, 2026

CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Replimune failed to address the FDA’s concerns with its study design contained in its Biologics License Application (“BLA”). Based on these facts, Replimune’s public statements were false and materially misleading throughout the class period.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

Join the case to recover your losses.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.